SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced today that it has appointed J. Scott Garland as executive vice president and chief commercial officer. The creation of this new executive management position reflects the company’s continued transformation into a commercial organization, and comes as Exelixis prepares for two major late-stage development milestones: the filing of a New Drug Application (NDA) for its lead compound, cabozantinib, for treatment of medullary thyroid cancer, expected to be completed in the first half of 2012; and the initiation of the first pivotal trial for cabozantinib in metastatic castration-resistant prostate cancer (CRPC), currently expected to start by the end of this year.
